JP5433415B2 - 粘膜炎を治療および予防するための方法 - Google Patents
粘膜炎を治療および予防するための方法 Download PDFInfo
- Publication number
- JP5433415B2 JP5433415B2 JP2009521373A JP2009521373A JP5433415B2 JP 5433415 B2 JP5433415 B2 JP 5433415B2 JP 2009521373 A JP2009521373 A JP 2009521373A JP 2009521373 A JP2009521373 A JP 2009521373A JP 5433415 B2 JP5433415 B2 JP 5433415B2
- Authority
- JP
- Japan
- Prior art keywords
- use according
- extract
- anthocyanosides
- mucositis
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028116 Mucosal inflammation Diseases 0.000 title claims description 29
- 201000010927 Mucositis Diseases 0.000 title claims description 29
- 238000000034 method Methods 0.000 title description 17
- 239000000284 extract Substances 0.000 claims description 53
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 claims description 16
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 14
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 14
- 244000001385 Sanguinaria canadensis Species 0.000 claims description 13
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 claims description 11
- 229930013397 isoquinoline alkaloid Natural products 0.000 claims description 11
- -1 pelargonidin glycosides Chemical class 0.000 claims description 10
- 244000133098 Echinacea angustifolia Species 0.000 claims description 8
- 229930015421 benzophenanthridine alkaloid Natural products 0.000 claims description 8
- 235000007336 cyanidin Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 235000014134 echinacea Nutrition 0.000 claims description 8
- 210000004392 genitalia Anatomy 0.000 claims description 6
- 229930182470 glycoside Natural products 0.000 claims description 6
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims description 6
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 235000007242 delphinidin Nutrition 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 claims description 4
- 240000007849 Macleaya cordata Species 0.000 claims description 4
- 241001455961 Macleaya microcarpa Species 0.000 claims description 4
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 claims description 4
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000006251 pelargonidin Nutrition 0.000 claims description 4
- 229940084560 sanguinarine Drugs 0.000 claims description 4
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 claims description 4
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 claims description 3
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 claims description 3
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 claims description 3
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 claims description 3
- JKHRCGUTYDNCLE-UHFFFAOYSA-O delphinidin Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 JKHRCGUTYDNCLE-UHFFFAOYSA-O 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- XVFMGWDSJLBXDZ-UHFFFAOYSA-O pelargonidin Chemical compound C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 XVFMGWDSJLBXDZ-UHFFFAOYSA-O 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 52
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 21
- 229930195725 Mannitol Natural products 0.000 description 21
- 239000000594 mannitol Substances 0.000 description 21
- 235000010355 mannitol Nutrition 0.000 description 21
- 229920002770 condensed tannin Polymers 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 16
- 239000003242 anti bacterial agent Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 13
- 229920001991 Proanthocyanidin Polymers 0.000 description 13
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 12
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 12
- 229940121375 antifungal agent Drugs 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 244000089698 Zanthoxylum simulans Species 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000003429 antifungal agent Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 229960004543 anhydrous citric acid Drugs 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 7
- 235000010358 acesulfame potassium Nutrition 0.000 description 7
- 229960004998 acesulfame potassium Drugs 0.000 description 7
- 239000000619 acesulfame-K Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- NSEWTSAADLNHNH-TXZJYACMSA-N Proanthocyanidin A-2 Natural products C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-TXZJYACMSA-N 0.000 description 6
- 229920002982 Procyanidin A2 Polymers 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 6
- 150000003797 alkaloid derivatives Chemical class 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229960001631 carbomer Drugs 0.000 description 6
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 229960002216 methylparaben Drugs 0.000 description 6
- NSEWTSAADLNHNH-UHFFFAOYSA-N pavetannin A-2 Natural products OC1CC2=C(O)C=C3OC(C4O)(C=5C=C(O)C(O)=CC=5)OC5=CC(O)=CC(O)=C5C4C3=C2OC1C1=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-UHFFFAOYSA-N 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229940068968 polysorbate 80 Drugs 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- NSEWTSAADLNHNH-LSBOWGMISA-N proanthocyanidin A2 Chemical compound C1([C@H]2OC3=C4[C@H]5C6=C(O)C=C(O)C=C6O[C@]([C@@H]5O)(OC4=CC(O)=C3C[C@H]2O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 NSEWTSAADLNHNH-LSBOWGMISA-N 0.000 description 6
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 6
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 6
- 229960003415 propylparaben Drugs 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical class CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 5
- 240000006365 Vitis vinifera Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 150000008622 benzophenanthridines Chemical class 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 5
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 5
- 150000005053 phenanthridines Chemical class 0.000 description 5
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 239000004201 L-cysteine Substances 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 235000021028 berry Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 235000002532 grape seed extract Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000008347 soybean phospholipid Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000000029 vaginal gel Substances 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 239000012675 alcoholic extract Substances 0.000 description 3
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 150000001907 coumarones Chemical class 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940044950 vaginal gel Drugs 0.000 description 3
- WEEFNMFMNMASJY-UHFFFAOYSA-M 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 WEEFNMFMNMASJY-UHFFFAOYSA-M 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 description 2
- 102000001974 Hyaluronidases Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930183665 actinomycin Natural products 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229930014669 anthocyanidin Natural products 0.000 description 2
- 235000008758 anthocyanidins Nutrition 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 2
- 229940064972 echinacea angustifolia extract Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000002178 gastroprotective effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002773 hyaluronidase Drugs 0.000 description 2
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 2
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 2
- 229940069510 parthenolide Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- COAWNPJQKJEHPG-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-1lambda^{4}-chromen-1-ylium chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 COAWNPJQKJEHPG-UHFFFAOYSA-N 0.000 description 1
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical class CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HBQJTBXZMPSVBP-UHFFFAOYSA-N Cyanidine Natural products OC1=CC(=C2/Oc3cc(O)cc(O)c3C=C2O)C=CC1=O HBQJTBXZMPSVBP-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229930182598 Eupomatenoid Natural products 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 241000218228 Humulus Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000555736 Sciurus vulgaris Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940047889 isobutyramide Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
1.Vaccinium myrtillus抽出物 100.0mg
2.Sanguinaria canadensisアルカロイド 6.0mg
3.マンニトール 688.0mg
4.キシリトール 600.0mg
5.グリセリルベヘネート 30.0mg
6.無水クエン酸 20.0mg
7.二酸化ケイ素 15.0mg
8.甘草香味料 15.0mg
9.ミント香味料 10.0mg
10.ステアリン酸マグネシウム 7.0mg
11.メントール結晶 5.0mg
12.アセサルフェームカリウム 4.0mg
メントール結晶は粉砕して微細粉末にし、適切な混合機(例えばV−ミキサー)を用い
て、製剤の他のすべての構成成分を混合した。次いで、粉末の混合物を適切な寸法の穴あけ器を備えている錠剤プレス機で圧縮し、1500mgの錠剤を得た。
1.塩化シアニジン 100.00mg
2.Sanguinaria canadensisアルカロイド 4.00mg
3.Zanthoxylum bungeanumの脂溶性抽出物 0.25mg
4.マンニトール 442.75mg
5.キシリトール 300.00mg
6.乳糖 100.00mg
7.グリセリルパルミトステアレート 50.00mg
8.メチルセルロース 40.00mg
9.ソフトフルーツ香味料 30.00mg
10.野菜硬化油 10.00mg
11.甘草香味料 10.00mg
12.ミント香味料 6.00mg
13.無水クエン酸 5.00mg
14.アセサルフェームカリウム 2.00mg
少量のマンニトールに吸収されたキシメンオイル(ximenoil)イソブチルアミドを塩化シアニジン、Sanguinaria canadensisアルカロイド、残りのマンニトール、キシリトール、乳糖、香味料および無水クエン酸と混合した。次いで粉末の混合物をメチルセルロースの含水アルコール溶液と混合した(湿式造粒法)。得られた混合物を10メッシュスクリーンに通し、ストーブで乾燥させ、20メッシュスクリーンでふるいにかけ、最終的に適切な混合機を用いて製剤の他の成分と混合した。粉末の混合物を適切な寸法の穴あけ器を備えている錠剤プレス機で圧縮し、1100mgの錠剤を得た。
1.Vaccinium myrtillusアルコール抽出物 40.0mg
2.サングリトリナム(sanguiritrinum) 2.0mg
4.グリセリルビハネート 30.0mg
5.無水クエン酸 20.0mg
6.粉末甘草ジュース 80.0mg
7.キシリトール 628.975mg
8.マンニトール 700.0mg
9.二酸化ケイ素 15.0mg
10.ペパーミント香味料 10.0mg
11.ステアリン酸マグネシウム 7.5mg
12.アセサルフェームカリウム 4.0mg
13.メントール 5.0mg
14.ヒドロキシプロピルセルロース 0.004mg
メントール結晶は粉砕して、微細な粉末を得た。Zanthoxylum bungeanum抽出物を少量のマンニトールに吸収させて、マンニトールの残りの部分および粉末のメントールと共に製剤の残りの成分と混合した。混合物を20メッシュスクリーンに通して、適切な寸法の穴あけ器で圧縮して1000mgの錠剤を得た。ヒドロキシプロピルセルロースを精製水に溶解させて錠剤に噴霧した。
1.Vaccinium myrtillusアルコール抽出物 40.0mg
2.Sanguinaria canadensisアルコール抽出物 2.0mg
3.Zanthoxylum bungeanum抽出精製物 0.025mg
4.大豆レシチン 30.0mg
5.無水クエン酸 5.0mg
6.L−システイン 5.0mg
7.乳糖 200.0mg
8.マンニトール 552.475mg
9.メチルセルロース 40.0mg
10.グリセリルパルミトステアレート 50.0mg
11.ベリー香味料 40.0mg
12.アセサルフェームカリウム 0.5mg
13.タルク 10.0mg
14.重炭酸ナトリウム 25.0mg
Zanthoxylum bungeanum抽出物を少量のマンニトールに吸収させて、マンニトールの残りの部分と共に製剤の残りの成分と混合した。混合物を20メッシュスクリーンに通して、適切な寸法の穴あけ器で圧縮して1000mgの錠剤を得た。
1.Vitis viniferaアルコール抽出物 80.0mg
2.Sanguinaria canadensisアルコール抽出物 2.0mg
3.Zanthoxylum bungeanum抽出精製物 0.025mg
4.大豆レシチン 30.0mg
5.無水クエン酸 5.0mg
6.L−システイン 5.0mg
7.乳糖 200.0mg
8.マンニトール 512.475mg
9.メチルセルロース 40.0mg
10.グリセリルパルミトステアレート 50.0mg
11.ベリー香味料 40.0mg
12.アセサルフェームカリウム 0.5mg
13.タルク 10.0mg
14.重炭酸ナトリウム 25.0mg
Zanthoxylum bungeanum抽出物を少量のマンニトールに吸収させて、マンニトールの残りの部分と共に製剤の残りの成分と混合した。混合物を20メッシュスクリーンに通して、適切な寸法の穴あけ器で圧縮して1000mgの錠剤を得た。
1.Vaccinium myrtillusアルコール抽出物 40.0mg
2.Sanguinaria canadensisアルコール抽出物 2.0mg
3.Echinacea angustifolia脂溶性抽出物 5.0mg
4.大豆レシチン 30.0mg
5.無水クエン酸 5.0mg
6.L−システイン 5.0mg
7.乳糖 200.0mg
8.マンニトール 547.5mg
9.メチルセルロース 40.0mg
10.グリセリルパルミトステアレート 50.0mg
11.ベリー香味料 40.0mg
12.アセサルフェームカリウム 0.5mg
13.タルク 10.0mg
14.重炭酸ナトリウム 25.0mg
Echinacea angustifolia抽出物を少量のマンニトールに吸収させて、マンニトールの残りの部分と共に製剤の残りの成分と混合した。混合物を20メッシュスクリーンに通して、適切な寸法の穴あけ器で圧縮して1000mgの錠剤を得た。
1.Vitis viniferaアルコール抽出物 80.0mg
2.Sanguinaria canadensisアルコール抽出物 2.0mg
3.Echinacea angustifolia脂溶性抽出物 5.0mg
4.大豆レシチン 30.0mg
5.無水クエン酸 5.0mg
6.L−システイン 5.0mg
7.乳糖 200.0mg
8.マンニトール 507.5mg
9.メチルセルロース 40.0mg
10.グリセリルパルミトステアレート 50.0mg
11.ベリー香味料 40.0mg
12.アセサルフェームカリウム 0.5mg
13.タルク 10.0mg
14.重炭酸ナトリウム 25.0mg
Echinacea angustifolia抽出物を少量のマンニトールに吸収させて、マンニトールの残りの部分と共に製剤の残りの成分と混合した。混合物を20メッシュスクリーンに通して、適切な寸法の穴あけ器で圧縮して1000mgの錠剤を得た。
シアニジン 250mg
乳糖 100mg
微晶質セルロース 100mg
架橋カルボキシルメチルセルロースナトリウム 45mg
コロイド状二酸化ケイ素 5mg
粉末を適切な混合機で混合し、得られた混合物を用いて、500mg/カプセルの量で硬質ゼラチンカプセルを満たした。
1.シアニジン 200mg
2.アンドログラフォリド 70mg
3.乳糖 100mg
4.微晶質セルロース 100mg
5.架橋カルボキシルメチルセルロースナトリウム 40mg
6.コロイド状二酸化ケイ素 5mg
7.ステアリン酸マグネシウム 5mg
実施例9の調製方法は、実施例8に記載した調製方法と同様である。
1.Vaccinium myrtillusのアルコール抽出物 100.0mg
2.ケリドニン 3.0mg
3.マンニトール 1200.0mg
4.マルトデキストリン 913.0mg
5.グアーガム 120.0mg
6.ヒドロキシプロピルセルロース 20.0mg
7.イチゴ香味料 15.0mg
8.無水クエン酸 15.0mg
9.アスパルテーム 10.0mg
10.ネオヘスペリジン 4.0mg
Vaccinium myrtillusのアルコール抽出物、ケリドニン、マンニトール、マルトデキストリン、グアーガム、無水クエン酸、アスパルテームおよびネオヘスペリジンを適切な混合機(例えば、V−ミキサー)で混合した。こうして得られた粉末の混合物を、ヒドロキシプロピルセルロースのアルコール溶液と混合した(湿式造粒法)。得られた混合物を10メッシュスクリーン上で粒状にし、真空下でストーブで乾燥し、20メッシュスクリーンを通してふるいにかけて香味料と混合した。こうして得られた粒子を2400mg/小袋の量で小袋に満たした。
1.プロアントシアニジンA2 1.0g
2.Sanguinaria canadensisアルカロイド 0.003g
3.プロピレングリコール 10.0g
4.エトキシジグリコール 10.0g
5.Softigen767 10.0g
6.ポリソルベート80 4.0g
7.カルボマー 2.0g
8.トリエタノールアミン20%溶液 2.0g
9.メチルパラベン 0.2g
10.プロピルパラベン 0.1g
11.精製水 100.0gまで十分量
プロアントシアニジンA2およびSanguinaria canadensisアルカロイドをプロピレングリコールおよびエトキシジグリコールの混合物に加えた。その溶液を加熱し、Softigen767を攪拌下で加えた。溶液を放置して冷まし、ポリソルベート80、メチルパラベンおよびプロピルパラベンを加えた。精製水をその溶液に加え、カルボマーを強い攪拌下で分散させた。溶液を真空下で脱気し、攪拌下20%トリエタノールアミン溶液でゲル化した。
1.プロアントシアニジンA2 1.0g
2.サンギナリン 0.002g
3.プロピレングリコール 10.0g
4.エトキシジグリコール 10.0g
5.Softigen767 10.0g
6.ポリソルベート80 4.0g
7.カルボマー 2.0g
8.トリエタノールアミン20%溶液 2.0g
9.メチルパラベン 0.2g
10.プロピルパラベン 0.1g
11.精製水 100.0gまで十分量
プロアントシアニジンA2およびサンギナリンをプロピレングリコールおよびエトキシジグリコールの混合物に加えた。その溶液を加熱し、Softigen767を攪拌下で加えた。溶液を放置して冷まし、ポリソルベート80、メチルパラベンおよびプロピルパラベンを加えた。精製水をその溶液に加え、カルボマーを強い攪拌下で分散させた。溶液を真空下で脱気し、攪拌下20%トリエタノールアミン溶液でゲル化した。
1.プロアントシアニジンA2 1.0g
2.ユポマテノイド6 0.012g
3.プロピレングリコール 10.0g
4.エトキシジグリコール 10.0g
5.Softigen767 10.0g
6.ポリソルベート80 4.0g
7.カルボマー 2.0g
8.トリエタノールアミン20%溶液 2.0g
9.メチルパラベン 0.2g
10.プロピルパラベン 0.1g
11.精製水 100.0gまで十分量
プロアントシアニジンA2およびユポマテノイド6をプロピレングリコールおよびエトキシジグリコールの混合物に加えた。その溶液を加熱し、Softigen767を攪拌下で加えた。溶液を放置して冷まし、ポリソルベート80、メチルパラベンおよびプロピルパラベンを加えた。精製水をその溶液に加え、カルボマーを強い攪拌下で分散させた。溶液を真空下で脱気し、攪拌下20%トリエタノールアミン溶液でゲル化した。
Claims (13)
- 粘膜炎を治療するための薬剤を調製するための、
・アントシアノサイドまたはアントシアノサイドを含む抽出物、
・ムラサキバレンギク(Echinacea angustifolia)の親油性抽出物、および
・イソキノリンアルカロイドまたはイソキノリンアルカロイドを含む抽出物、
を組み合わせた使用。 - 前記アントシアノサイドが、シアニジン、デルフィニジンもしくはペラルゴニジンの配糖体、または対応するアグリコンを含む、請求項1に記載の使用。
- 前記アントシアノサイドを含む前記抽出物が、シアニジン、デルフィニジンもしくはペラルゴニジンの配糖体、または対応するアグリコンを含む植物抽出物である、請求項1に記載の使用。
- 前記アントシアノサイドを含む前記抽出物が、セイヨウスノキ(Vaccinium myrtillus)由来である、請求項1に記載の使用。
- 前記イソキノリンアルカロイドが、ベンゾフェナントリジンアルカロイドまたはベンゾフェナントリジンアルカロイドを含む抽出物を含む、請求項1に記載の使用。
- 前記イソキノリンアルカロイドが、サンギナリン、ケレリスリン、ケリドニン、ユポマテノイド、あるいはアカネグサ(Sanguinaria Canadensis)、タケニグサ(Macleaya cordata)またはミクロカルパ(Macleaya microcarpa)の抽出物を含む、請求項5に記載の使用。
- 前記アントシアノサイドまたはアントシアノサイドを含む抽出物を、単位用量当たり50mg〜500mg含む、請求項1に記載の使用。
- 前記アントシアノサイドまたはアントシアノサイドを含む抽出物の治療有効量が、一日当たり3000mg以下である、請求項1に記載の使用。
- 前記粘膜炎が患者の胃腸管の一部、性器または皮膚に生じる、請求項1に記載の使用。
- 前記粘膜炎が患者の口に生じる請求項1に記載の使用。
- 前記粘膜炎が患者に抗がん化学療法薬を投与することに関与して生じる、請求項1に記載の使用。
- 前記薬剤が、セイヨウスノキ(Vaccinium myrtillus)の抽出物、アカネグサ(Sanguinaria canadensis)、タケニグサ(Macleaya cordata)またはミクロカルパ(Macleaya microcarpa)から抽出されたイソキノリンアルカロイド、およびムラサキバレンギク(Echinacea angustifolia)の抽出物を含む、請求項1に記載の使用。
- 前記薬剤が経口または局所投与により投与される、請求項12に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06015732A EP1882473A1 (en) | 2006-07-28 | 2006-07-28 | Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs |
EP06015732.8 | 2006-07-28 | ||
PCT/IB2007/002147 WO2008012666A2 (en) | 2006-07-28 | 2007-07-27 | Treatment and prevention mucositis by anthocyanidin derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009544687A JP2009544687A (ja) | 2009-12-17 |
JP5433415B2 true JP5433415B2 (ja) | 2014-03-05 |
Family
ID=37309334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009521373A Expired - Fee Related JP5433415B2 (ja) | 2006-07-28 | 2007-07-27 | 粘膜炎を治療および予防するための方法 |
Country Status (20)
Country | Link |
---|---|
US (3) | US20080026058A1 (ja) |
EP (4) | EP1882473A1 (ja) |
JP (1) | JP5433415B2 (ja) |
KR (1) | KR20090052852A (ja) |
CN (1) | CN101495114A (ja) |
AU (1) | AU2007278959B2 (ja) |
BR (1) | BRPI0715364A2 (ja) |
CA (2) | CA2935902C (ja) |
DK (2) | DK2520295T3 (ja) |
ES (2) | ES2602786T3 (ja) |
HU (2) | HUE031941T2 (ja) |
IL (1) | IL196737A (ja) |
MX (1) | MX2009001064A (ja) |
NO (1) | NO341742B1 (ja) |
PL (2) | PL2520295T3 (ja) |
PT (2) | PT2520295T (ja) |
RU (1) | RU2438693C2 (ja) |
SG (1) | SG172745A1 (ja) |
SI (2) | SI2520295T1 (ja) |
WO (1) | WO2008012666A2 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20042414A1 (it) * | 2004-12-17 | 2005-03-17 | Indena Spa | Formulazione per il trattamento di affezioni delle prime vie respiratorie |
ITMI20080038A1 (it) * | 2008-01-11 | 2009-07-12 | Indena Spa | Formulazioni per il trattamento di mucositi indotte da terapia antitumorale o immunosoppressiva |
ITMI20080395A1 (it) | 2008-03-10 | 2009-09-11 | Indena Spa | Formulazioni per il trattamento delle verruche e delle placche psoriatiche |
EP2133079B1 (en) * | 2008-06-12 | 2011-10-05 | Indena S.p.A. | Compositions for the treatment of vaginal infections with chronic inflammation |
EP2268276A1 (en) * | 2008-04-24 | 2011-01-05 | Indena S.p.A. | Compositions for the treatment and prevention of infections of the oral cavity |
RU2504379C2 (ru) * | 2008-04-24 | 2014-01-20 | Индена С.П.А. | Композиции для лечения вагинальных инфекций с хроническим воспалением |
ES2334746B1 (es) * | 2008-07-23 | 2011-01-28 | Feedback Trayer, S.L. | Producto para la higiene intima a base de mirtillo rojo y procedimiento para su preparacion. |
JP2010215532A (ja) * | 2009-03-13 | 2010-09-30 | Ands Corporation | コラーゲンゲル収縮促進剤 |
EP2344154B1 (en) | 2009-10-21 | 2016-12-07 | Maqui New Life S.A. | Compositions that include anthocyanidins and methods of use |
IT1402749B1 (it) | 2010-10-28 | 2013-09-18 | Indena Spa | Composizioni per il trattamento di ulcere periferiche di varia origine |
FR2979241B1 (fr) | 2011-08-30 | 2014-05-09 | Nutrialys Medical Nutrition Sa | Utilisation de compositions a faible teneur en polyamines dans la prevention ou le traitement des effets indesirables lies a un traitement anti-cancereux |
ITMI20111671A1 (it) * | 2011-09-16 | 2013-03-17 | Indena Spa | Composizioni per il trattamento di ulcere periferiche di varia origine |
CN104145966B (zh) * | 2014-07-23 | 2016-09-07 | 中国人民解放军第二军医大学 | 白屈菜红碱在制备抗真菌生物被膜药物中的应用 |
JP6700084B2 (ja) * | 2016-03-30 | 2020-05-27 | 株式会社ファンケル | コーティング顆粒 |
JP6700083B2 (ja) * | 2016-03-30 | 2020-05-27 | 株式会社ファンケル | 口腔内速崩壊錠 |
CN106361755A (zh) * | 2016-10-23 | 2017-02-01 | 徐州诺克非医药科技有限公司 | 含Zoarenone用于治疗溃疡性结肠炎的药物 |
CN110636760B (zh) * | 2016-10-27 | 2023-04-14 | Nse产品公司 | 肠道健康促进组合物 |
CN108721276B (zh) * | 2018-06-29 | 2020-01-07 | 佛山科学技术学院 | 一种小白菊内酯和原花青素复方药物组合物及其用途 |
CN109549946B (zh) * | 2019-01-08 | 2020-12-18 | 牡丹江医学院 | 一种治疗咽炎的药物及其制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4145412A (en) * | 1977-02-14 | 1979-03-20 | Vipont Chemical Company | Composition for application to oral cavity and method for preparation thereof |
GB2062991B (en) * | 1979-11-07 | 1983-11-16 | Image Data Products Ltd | Position co-ordinates digitiser |
US4818533A (en) * | 1985-07-09 | 1989-04-04 | Vipont Pharmaceutical, Inc. | Production of high purity alkaloids |
IT1231725B (it) * | 1989-08-11 | 1991-12-21 | Inverni Della Beffa Spa | Procedimento per la preparazione di estratti ad alto contenuto in antocianosidi. |
ES2075187T3 (es) | 1990-07-05 | 1995-10-01 | Indena Spa | Extractos de equinaceas, un procedimiento para su preparacion y formulaciones que los contienen. |
JP2754906B2 (ja) * | 1990-11-06 | 1998-05-20 | 日本電気株式会社 | 半導体集積回路 |
US5073368A (en) * | 1991-05-15 | 1991-12-17 | Colgate-Palmolive Company | Sanguinaria mouthrinse having improved anti microbial activity and stability |
US5378465A (en) | 1993-05-24 | 1995-01-03 | Zeines; Victor | Solution for application to an oral cavity |
IT1270999B (it) * | 1994-07-26 | 1997-05-26 | Indena Spa | Formulazioni a base di cumarine e loro uso in campo farmaceutico e cosmetico |
NO943860D0 (no) * | 1994-10-13 | 1994-10-13 | Unifob | En kjemisk forbindelse og et preparat til bruk som terapeutikum |
WO1997041137A1 (en) * | 1996-04-17 | 1997-11-06 | Unifob | Use of anthocyanidin and anthocyanidin derivatives |
US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
ITMI981542A1 (it) | 1998-07-07 | 2000-01-07 | Indena Spa | Estratti di zanthoxylum bungeanum e loro formulazioni farmaceutiche e cosmetiche |
US6162393A (en) * | 1998-08-06 | 2000-12-19 | Ndt, Inc. | Contact lens and ophthalmic solutions |
JP2001039844A (ja) * | 1999-07-29 | 2001-02-13 | Kikkoman Corp | 咽喉用うがい剤 |
WO2001015553A1 (en) * | 1999-08-27 | 2001-03-08 | Michigan State University | Dietary food supplement containing natural cyclooxygenase inhibitors |
ITMI20000628A1 (it) * | 2000-03-24 | 2001-09-24 | Indena Spa | Composizioni cosmetiche ritardanti la ricrescita dei peli |
AT500455B1 (de) * | 2000-09-15 | 2007-08-15 | Roth Hermann Dr | Verwendung von benzophenanthridinalkaloiden als futteradditiv |
ATE525061T1 (de) * | 2001-02-28 | 2011-10-15 | Axiomedic Ltd | Feste selbst-haftende zusammensetzungen zur topischen behandlung von störungen der mundschleimhaut |
WO2002092028A2 (en) * | 2001-05-15 | 2002-11-21 | The Procter & Gamble Company | Oral care compositions |
IL143318A0 (en) * | 2001-05-23 | 2002-04-21 | Herbal Synthesis Corp | Herbal compositions for the treatment of mucosal lesions |
US6596313B2 (en) * | 2001-08-06 | 2003-07-22 | The Quigley Corporation | Nutritional supplement and methods of using it |
US20030105027A1 (en) * | 2001-11-06 | 2003-06-05 | Rosenbloom Richard A. | Nutritional supplements and methods for prevention, reduction and treatment of radiation injury |
US20050222250A1 (en) * | 2002-04-16 | 2005-10-06 | Mohiaddin Rezvani | Curcumin for the prevention and/or treatment of tissue damage |
US7790762B2 (en) * | 2002-10-31 | 2010-09-07 | National Jewish Health | Compounds and methods for thiol-containing compound efflux and cancer treatment |
GB0230042D0 (en) * | 2002-12-23 | 2003-01-29 | Britannia Pharmaceuticals Ltd | Composition comprising plant extract and a sugar for use in inhibiting bacterial proliferation |
FR2856304B1 (fr) * | 2003-06-20 | 2006-03-03 | Natural Product Consulting | Composition pour la prevention des infections du systeme urinaire |
ITMI20032287A1 (it) * | 2003-11-24 | 2005-05-25 | Indena Spa | Composizioni per il trattamento delle affezioni del cavo orale e delle prime vie respiratorie |
RU2383353C2 (ru) * | 2004-04-28 | 2010-03-10 | Хатчисон Медифарма Энтерпрайзис Лимитед | Суммарные экстракты из andrographis paniculata |
WO2006024545A1 (en) * | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
ITMI20042414A1 (it) * | 2004-12-17 | 2005-03-17 | Indena Spa | Formulazione per il trattamento di affezioni delle prime vie respiratorie |
US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
CA2622286A1 (en) * | 2005-09-27 | 2007-04-05 | University Of Kentucky Research Foundation | Anti-inflammatory composition comprising berry extract |
-
2006
- 2006-07-28 EP EP06015732A patent/EP1882473A1/en not_active Withdrawn
-
2007
- 2007-07-27 SG SG2011049319A patent/SG172745A1/en unknown
- 2007-07-27 PT PT121774863T patent/PT2520295T/pt unknown
- 2007-07-27 CA CA2935902A patent/CA2935902C/en not_active Expired - Fee Related
- 2007-07-27 ES ES12177486.3T patent/ES2602786T3/es active Active
- 2007-07-27 CN CNA2007800277421A patent/CN101495114A/zh active Pending
- 2007-07-27 MX MX2009001064A patent/MX2009001064A/es active IP Right Grant
- 2007-07-27 PL PL12177486T patent/PL2520295T3/pl unknown
- 2007-07-27 HU HUE07804655A patent/HUE031941T2/en unknown
- 2007-07-27 DK DK12177486.3T patent/DK2520295T3/en active
- 2007-07-27 HU HUE12177486A patent/HUE031034T2/en unknown
- 2007-07-27 BR BRPI0715364-3A patent/BRPI0715364A2/pt not_active Application Discontinuation
- 2007-07-27 EP EP12177483A patent/EP2522345A1/en not_active Withdrawn
- 2007-07-27 JP JP2009521373A patent/JP5433415B2/ja not_active Expired - Fee Related
- 2007-07-27 DK DK07804655.4T patent/DK2046324T3/en active
- 2007-07-27 SI SI200731833A patent/SI2520295T1/sl unknown
- 2007-07-27 EP EP07804655.4A patent/EP2046324B1/en not_active Not-in-force
- 2007-07-27 RU RU2009102649/15A patent/RU2438693C2/ru not_active IP Right Cessation
- 2007-07-27 WO PCT/IB2007/002147 patent/WO2008012666A2/en active Application Filing
- 2007-07-27 PL PL07804655T patent/PL2046324T3/pl unknown
- 2007-07-27 ES ES07804655.4T patent/ES2629306T3/es active Active
- 2007-07-27 CA CA2659211A patent/CA2659211C/en not_active Expired - Fee Related
- 2007-07-27 AU AU2007278959A patent/AU2007278959B2/en not_active Ceased
- 2007-07-27 US US11/829,138 patent/US20080026058A1/en not_active Abandoned
- 2007-07-27 EP EP12177486.3A patent/EP2520295B1/en not_active Not-in-force
- 2007-07-27 KR KR1020097001679A patent/KR20090052852A/ko active Search and Examination
- 2007-07-27 SI SI200731926A patent/SI2046324T1/sl unknown
- 2007-07-27 PT PT78046554T patent/PT2046324T/pt unknown
-
2009
- 2009-01-27 IL IL196737A patent/IL196737A/en active IP Right Grant
- 2009-02-26 NO NO20090887A patent/NO341742B1/no not_active IP Right Cessation
-
2010
- 2010-08-16 US US12/856,786 patent/US9730952B2/en not_active Expired - Fee Related
-
2017
- 2017-07-12 US US15/648,064 patent/US20170304341A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5433415B2 (ja) | 粘膜炎を治療および予防するための方法 | |
KR101545366B1 (ko) | 천심련 추출물 | |
EP0971743B1 (de) | Stabilisiertes arzneimittel enthaltend cysteinylderivate | |
KR19980069961A (ko) | 항문직장 및 결장 질병의 제어 및 치료를 위한 신규 약제학적조성물 및 그 제조방법 | |
US20040229939A1 (en) | Tetrahydrocannabinol compositions and methods of manufacture and use thereof | |
JP5357896B2 (ja) | 抗腫瘍療法または免疫抑制療法によって誘導される粘膜炎の治療のための製剤 | |
ES2284083T3 (es) | Composiciones farmaceuticas que comprenden un extracto de euphorbia prostata. | |
US20150011622A1 (en) | Dosage Form Containing Extract From Bark of Liriodendron Tulipifera as Active Ingredient | |
US20110091536A1 (en) | Compositions comprising euphorbia prostrata and process of preparation thereof | |
JPH10218780A (ja) | 肛門直腸疾患および結腸疾患の制御および処置のための新規な薬学組成物およびその製造方法 | |
JP2018188377A (ja) | 医薬組成物 | |
US20230405068A1 (en) | Radiation-induced fibrosis treatment | |
KR20120116871A (ko) | 이관개방증 치료제 | |
JP2004091477A (ja) | アレルギー疾患治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100715 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130520 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130527 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131119 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131209 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5433415 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |